BioVersys to Present Key Data at ESCMID Global 2026

BioVersys AG, a clinical-stage biopharmaceutical company from Basel, Switzerland, will present data on their leading assets at ESCMID Global 2026 in Munich. The conference hosts experts from various regions who will discuss BV100's efficacy against carbapenem-resistant Acinetobacter baumannii and BV500's potential against non-tuberculosis mycobacteria.

BV100, in Phase 3 trials, is being reviewed for its impact on hospital-acquired bacterial pneumonia, offering significant potential due to its promising in vitro results. It has already received a Qualified Infectious Disease Product Designation from the FDA.

BV500, originating from BioVersys's Ansamycin Chemistry platform, shows strong in vitro and in vivo activity against mycobacteria. The company collaborates with Shionogi & Co. for further development.

The CEO of BioVersys, Marc Gitzinger, will highlight the importance of funding and policy in infectious disease research during the conference. These efforts underline BioVersys's commitment to addressing antimicrobial resistance.